|
Editas Medicine, Inc. (Editar) Avaliação DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Editas Medicine, Inc. (EDIT) Bundle
Avalie as perspectivas financeiras da Editas Medicine, Inc. (editar) como um especialista! Essa calculadora DCF (editar) fornece dados financeiros pré-preenchidos e flexibilidade total para modificar o crescimento da receita, o WACC, as margens e outras suposições essenciais para se alinhar às suas previsões.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.5 | 90.7 | 25.5 | 19.7 | 78.1 | 98.7 | 124.7 | 157.5 | 199.0 | 251.4 |
| Revenue Growth, % | 0 | 341.93 | -71.85 | -22.83 | 296.32 | 26.33 | 26.33 | 26.33 | 26.33 | 26.33 |
| EBITDA | -138.1 | -130.9 | -188.1 | -219.6 | -163.1 | -98.7 | -124.7 | -157.5 | -199.0 | -251.4 |
| EBITDA, % | -672.6 | -144.25 | -736.35 | -1114.11 | -208.8 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 2.8 | 4.0 | 5.1 | 6.3 | 6.1 | 15.4 | 19.4 | 24.5 | 31.0 | 39.1 |
| Depreciation, % | 13.78 | 4.36 | 19.78 | 32.15 | 7.76 | 15.57 | 15.57 | 15.57 | 15.57 | 15.57 |
| EBIT | -140.9 | -134.8 | -193.1 | -226.0 | -169.2 | -98.7 | -124.7 | -157.5 | -199.0 | -251.4 |
| EBIT, % | -686.39 | -148.61 | -756.13 | -1146.26 | -216.56 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 457.1 | 511.8 | 619.9 | 437.4 | 323.1 | 98.7 | 124.7 | 157.5 | 199.0 | 251.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .4 | 6.0 | .3 | 5.1 | 10.2 | 9.6 | 12.2 | 15.4 | 19.5 | 24.6 |
| Account Receivables, % | 2.04 | 6.67 | 1.05 | 26.1 | 13.04 | 9.78 | 9.78 | 9.78 | 9.78 | 9.78 |
| Inventories | .0 | -109.7 | -120.1 | -93.1 | .0 | -59.2 | -74.8 | -94.5 | -119.4 | -150.8 |
| Inventories, % | 0 | -120.87 | -470.05 | -472.29 | 0 | -60 | -60 | -60 | -60 | -60 |
| Accounts Payable | 5.8 | 6.4 | 5.1 | 9.5 | 8.3 | 22.5 | 28.5 | 36.0 | 45.4 | 57.4 |
| Accounts Payable, % | 28.46 | 7.06 | 19.77 | 48.25 | 10.58 | 22.83 | 22.83 | 22.83 | 22.83 | 22.83 |
| Capital Expenditure | -6.2 | -7.2 | -8.0 | -4.1 | -4.7 | -19.0 | -24.0 | -30.3 | -38.2 | -48.3 |
| Capital Expenditure, % | -30.04 | -7.89 | -31.23 | -20.89 | -6.04 | -19.22 | -19.22 | -19.22 | -19.22 | -19.22 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -130.1 | -127.2 | -185.7 | -209.5 | -169.2 | -93.9 | -118.6 | -149.8 | -189.2 | -239.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -128.0 | -25.8 | -173.8 | -234.6 | -267.2 | -23.5 | -104.1 | -131.6 | -166.2 | -210.0 |
| WACC, % | 11.29 | 11.31 | 11.33 | 11.3 | 11.36 | 11.32 | 11.32 | 11.32 | 11.32 | 11.32 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -431.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -214 | |||||||||
| Terminal Value | -2,299 | |||||||||
| Present Terminal Value | -1,345 | |||||||||
| Enterprise Value | -1,776 | |||||||||
| Net Debt | -87 | |||||||||
| Equity Value | -1,689 | |||||||||
| Diluted Shares Outstanding, MM | 76 | |||||||||
| Equity Value Per Share | -22.24 |
What You Will Receive
- Comprehensive Financial Model: Editas Medicine’s actual data facilitates accurate DCF valuation.
- Complete Forecast Control: Modify revenue growth, margins, WACC, and other essential drivers.
- Real-Time Calculations: Automatic updates provide immediate results as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, allowing repeated application for in-depth forecasts.
Key Features
- Comprehensive Data: Editas Medicine's historical financial reports and pre-filled projections.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: View Editas Medicine's intrinsic value update instantly.
- Intuitive Visuals: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the pre-built Excel file containing Editas Medicine, Inc.'s (EDIT) financial data.
- Customize: Modify forecasts, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and instantly compare results.
- Make Decisions: Leverage the valuation outcomes to inform your investment strategy.
Why Choose Editas Medicine, Inc. (EDIT)?
- Innovative Solutions: Pioneering gene-editing technology to transform medicine.
- Expert Team: Led by industry leaders dedicated to advancing genetic research.
- Robust Pipeline: A diverse portfolio of therapies targeting serious diseases.
- Commitment to Quality: Adhering to the highest standards in research and development.
- Strong Partnerships: Collaborating with top organizations to enhance scientific progress.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for assessing investments in Editas Medicine, Inc. (EDIT).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights to clients interested in Editas Medicine, Inc. (EDIT).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotechnology firms like Editas Medicine, Inc. (EDIT) are assessed in the market.
What the Template Contains
- Preloaded EDIT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.